Publication | Closed Access

Randomized, Double-Masked, Sham-Controlled Trial of Ranibizumab for Neovascular Age-Related Macular Degeneration: PIER Study Year 2

Ocular DiseaseOphthalmologyExperimental OphthalmologyAge-related DiseasesSham-controlled TrialGlaucomaRetinal TherapiesMedicine